| Trial ID: | L0326 |
| Source ID: | NCT05041673
|
| Associated Drug: |
Metformin
|
| Title: |
Anti-diabetic Drugs and Fatty Liver Management
|
| Acronym: |
--
|
| Status: |
Active, not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Fatty Liver, Nonalcoholic|Diabetes Mellitus, Type 2
|
| Interventions: |
Drug: Metformin
|
| Outcome Measures: |
Change in steatosis as measured using CAP score (fibroscan) and MRI|Change in liver enzymes|Changes in fibrosis grade
|
| Sponsor/Collaborators: |
Alexandria University|Eva Pharma
|
| Gender: |
All
|
| Age: |
18 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Not applicable
|
| Enrollment: |
120
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
February 23, 2021
|
| Completion Date: |
September 30, 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
January 18, 2022
|
| Locations: |
Alexandria University., Alexandria, Egypt
|
| URL: |
https://ClinicalTrials.gov/show/NCT05041673
|
